Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001636587-25-000027
Filing Date
2025-05-22
Accepted
2025-05-22 16:49:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 17081
2 05/22/25 exhibit991acorn.pdf EX-99.1 CHARTER 95260
  Complete submission text file 0001636587-25-000027.txt   150259
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Subject) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-92480 | Film No.: 25977937
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 295 MADISON AVENUE 32ND FL NEW YORK NY 10017
Business Address 295 MADISON AVENUE 32ND FL NEW YORK NY 10017 917-940-2732
ACORN BIOVENTURES, L.P. (Filed by) CIK: 0001766853 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D